Patents by Inventor Juan I. Luengo

Juan I. Luengo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9790212
    Abstract: This invention relates to novel compounds according to Formula (III)(a) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: October 17, 2017
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Charles William Blackledge, Jr., Joelle Lorraine Burgess, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Louis V. LaFrance, III, Juan I. Luengo, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Mark Schulz, Dai-Shi Su, Xinrong Tian
  • Publication number: 20170029412
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: October 13, 2016
    Publication date: February 2, 2017
    Inventors: Charles William BLACKLEDGE, JR., Joelle Lorraine BURGESS, Neil W. JOHNSON, Jiri KASPAREC, Steven David KNIGHT, Louis V. LaFRANCE, III, Juan I. LUENGO, William Henry MILLER, Kenneth Allen NEWLANDER, Stuart Paul ROMERIL, Mark SCHULZ, Dai-Shi SU, Xinrong TIAN
  • Patent number: 9505745
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: November 29, 2016
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Charles William Blackledge, Jr., Joelle Lorraine Burgess, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Louis V. LaFrance, III, Juan I. Luengo, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Mark Schulz, Dai-Shi Su, Xinrong Tian
  • Publication number: 20160102083
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: April 25, 2014
    Publication date: April 14, 2016
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Charles William BLACKLEDGE, JR., Joelle Lorraine BURGESS, Neil W. JOHNSON, Jiri KASPAREC, Steven David KNIGHT, Louis V. LaFRANCE, III, Juan I. LUENGO, William Henry MILLER, Kenneth Allen NEWLANDER, Stuart Paul ROMERIL, Mark SCHULZ, Dai-Shi SU, Xinrong TIAN
  • Patent number: 8410095
    Abstract: This invention relates to novel compounds of formula (I): and derivatives thereof useful for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: April 2, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Hong Lin, Juan I. Luengo, Ralph A. Rivero, Mark James Schulz, Ren Xie, Jin Zeng
  • Publication number: 20130078213
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Application
    Filed: August 24, 2012
    Publication date: March 28, 2013
    Inventors: Kevin J. Duffy, Connie Erickson-Miller, Daniel F. Eppley, Julian Jenkins, Juan I. Luengo, Nannan Liu, Alan T. Price, Antony N. Shaw, Sophie Visonneau, Kenneth Wiggall
  • Publication number: 20120053147
    Abstract: This invention relates to novel compounds of formula (I): and derivatives thereof useful for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K}, PI3K?, and/or PI3K?.
    Type: Application
    Filed: May 20, 2010
    Publication date: March 1, 2012
    Inventors: Hong Lin, Juan I Luengo, Ralph A. Rivero, Mark James Schulz, Ren Xie, Jin Zeng
  • Publication number: 20110212054
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Application
    Filed: August 3, 2010
    Publication date: September 1, 2011
    Inventors: Kevin J. Duffy, Connie Erickson-Miller, Julian Jenkins, Juan I. Luengo
  • Patent number: 7790704
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: September 7, 2010
    Assignee: GlaxoSmithKline, LLC
    Inventors: Kevin J. Duffy, Connie Erickson-Miller, Julian Jenkins, Juan I. Luengo
  • Patent number: 7674887
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: March 9, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Kevin J. Duffy, Juan I. Luengo, Antony N. Shaw, Kenneth Wiggall
  • Patent number: 7648971
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: January 19, 2010
    Assignee: SmithKline Beecham Corp.
    Inventors: Kevin J. Duffy, Connie Erickson-Miller, Julian Jenkins, Juan I. Luengo, Sophie Visonneau
  • Publication number: 20090176973
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Application
    Filed: June 18, 2008
    Publication date: July 9, 2009
    Inventors: Kevin J. Duffy, Connie Erickson-Miller, Daniel F. Eppley, Julian Jenkins, Juan I. Luengo, Nannan Liu, Alan T. Price, Antony N. Shaw, Sophie Visonneau, Kenneth Wiggall
  • Publication number: 20090176746
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Application
    Filed: June 18, 2008
    Publication date: July 9, 2009
    Inventors: Kevin J Duffy, Connie Erickson-Miller, Daniel F. Eppley, Julian Jenkins, Juan I. Luengo, Nannan Liu, Alan T. Price, Antony N. Shaw, Sophie Visonneau, Kenneth Wiggall
  • Publication number: 20090155203
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Application
    Filed: June 18, 2008
    Publication date: June 18, 2009
    Inventors: Kevin J. Duffy, Connie Erickson-Miller, Daniel F. Eppley, Julian Jenkins, Juan I. Luengo, Nannan Liu, Alan T. Price, Antony N. Shaw, Sophie Visonneau, Kenneth Wiggal
  • Publication number: 20090137557
    Abstract: Novel calcilytic compounds, pharmaceutical compositions, methods of synthesis and methods of using them are provided.
    Type: Application
    Filed: November 21, 2006
    Publication date: May 28, 2009
    Inventors: Thomas Wen Fu Ku, Hong Lin, Juan I. Luengo, Robert W. Marquis Jr., Joshi M. Ramanjulu, Robert Trout, Dennis S. Yamashita
  • Patent number: 7473686
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Grant
    Filed: January 8, 2007
    Date of Patent: January 6, 2009
    Assignee: SmithKline Beecham Corp.
    Inventors: Kevin J. Duffy, Connie Erickson-Miller, Julian Jenkins, Juan I. Luengo, Sophie Visonneau
  • Patent number: 7452874
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Grant
    Filed: January 8, 2007
    Date of Patent: November 18, 2008
    Assignee: SmithKline Beecham Corp.
    Inventors: Kevin J. Duffy, Juan I. Luengo, Antony N. Shaw, Kenneth Wiggall
  • Patent number: 7439342
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Grant
    Filed: January 8, 2007
    Date of Patent: October 21, 2008
    Assignee: Smith Kline Beecham Corp.
    Inventors: Kevin J. Duffy, Juan I. Luengo
  • Publication number: 20080214640
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Application
    Filed: January 8, 2007
    Publication date: September 4, 2008
    Inventors: Kevin J. Duffy, Connie Erickson-Miller, Daniel F. Eppley, Julian Jenkins, Juan I. Luengo, Nannan Liu, Alan T. Price, Antony N. Shaw, Sophie Visonneau, Kenneth Wiggall
  • Patent number: 7335649
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: February 26, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: Kevin J. Duffy, Connie Erickson-Miller, Julian Jenkins, Juan I. Luengo, Sophie Visonneau